| Date | Title | Description |
| 24.08.2026 | Craif Fuels US Cancer Fight with $33M | Craif secures $33 million in Series D funding. The bio-AI firm targets advanced non-invasive cancer detection. Its platform analyzes microRNA from urine. The company focuses on early diagnosis. Pancreatic cancer is a primary target. US mark... |
| 18.08.2026 | Craif Secures $33M to Bring AI-Powered Urine Oncology Diagnostics to the U.S. | What You Should Know
Craif Inc., a bio-AI company developing a non-invasive urine analysis platform for early cancer detection, closed an approximately $33M Series D round (¥5.28 billion), bringing its total capital raised to roughly $88M (... |
| 18.08.2026 | Craif Raises $33M to Advance US Cancer Testing Platform | Craif Raises Series D for Cancer Detection
Craif has raised approximately $33 million in Series D financing to advance early cancer detection technology. The round included $30.7 million in equity and $3.3 million in debt. Granite-Integral ... |
| 18.08.2026 | DefendEye Closes Funding | DefendEye, a Hallandale Beach, FL-based provider of fully autonomous aerial intelligence systems and drones, raised an undisclosed amount in new funding.
The round was led by NovaCapital with participation from ff Venture Capital, Hard2beat... |
| 15.06.2026 | Инновации и потенциал: кто попал в финал премии Всемирной организации интеллектуальной собственности | Всемирная организация интеллектуальной собственности (ВОИС) с 2022 года проводит отбор в рамках международной премии WIPO Global Awards 2026. В этом году на конкурс было подано свыше 1300 заявок из 126 стран мира. Эксперты определили 33 фин... |
| 28.04.2025 | Japanese cancer detection startup Craif raises $22m, eyes US expansion | Craif Inc, a Japanese molecular diagnostics company focused on early cancer detection, has announced raising $22 million in a Series C funding round. |
| 20.09.2024 | Craif presents research results on early detection of pancreatic cancer using microRNA at the 65th Academic Conference of the Japanese Society for Physical Examination and Preventive Medicine | Craif presents research results on early detection of pancreatic cancer using microRNA at the 65th Academic Conference of the Japanese Society for Physical Examination and Preventive Medicine
*Craif Co., Ltd.*
Press release: September 20, 2... |
| 17.07.2024 | New idea! New product “MySignal Check”, a simple test that helps prevent cancer, goes on sale today, July 17th (Wednesday) | New idea! New product “MySignal Check”, a simple test that helps prevent cancer, goes on sale today, July 17th (Wednesday)
*Craif Co., Ltd.*
Press release: July 17, 2024
**
New idea! New product “MySignal Check”, a simple test that helps pr... |
| 17.07.2024 | New idea! New product “MySignal Check”, a simple test that helps prevent cancer, goes on sale today, July 17th (Wednesday) | - |
| 19.06.2024 | Craif develops a “quick and easy screening kit” that leads to early detection and treatment of spinal muscular atrophy (SMA), an incurable disease in newborns | Craif Co., Ltd.
Craif develops a “quick and easy screening kit” that leads to early detection and treatment of spinal muscular atrophy (SMA), an incurable disease in newborns
～Presented at the 65th Academic Conference of the Japanese Societ... |
| 19.06.2024 | Craif develops a “quick and easy screening kit” that leads to early detection and treatment of spinal muscular atrophy (SMA), an incurable disease in newborns | - |
| 10.06.2024 | Craif selected as a finalist in the world’s largest medical technology accelerator’s “Medtech Innovator 2024 Cohort” | Craif Co., Ltd.
Craif selected as a finalist in the world’s largest medical technology accelerator’s “Medtech Innovator 2024 Cohort”
……
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter “Craif”), which provides th... |
| 10.06.2024 | Craif selected as a finalist in the world’s largest medical technology accelerator’s “Medtech Innovator 2024 Cohort” | - |
| 30.05.2024 | Craif presents the results of joint research on breast cancer with Cancer Research Society Ariake Hospital at the 33rd Japan Cancer Pathology Treatment Study Group | - |
| 30.05.2024 | Craif presents the results of joint research on breast cancer with Cancer Research Society Ariake Hospital at the 33rd Japan Cancer Pathology Treatment Study Group | Craif Co., Ltd.
Craif presents the results of joint research on breast cancer with Cancer Research Society Ariake Hospital at the 33rd Japan Cancer Pathology Treatment Study Group
……
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi... |
| 08.04.2024 | The number of medical institutions that have introduced the next-generation cancer risk test “MySignal (R)️” h as exceeded 600! | Craif Co., Ltd.
The number of medical institutions that have introduced the
next-generation cancer risk test “MySignal (R)️” has exceeded 600! ~Increasingly used in a wide range of situations, including
incorporation into mobile medical exa... |
| 08.04.2024 | The number of medical institutions that have introduced the next-generation cancer risk test “MySignal (R)️” h as exceeded 600! | - |
| 21.01.2024 | Craif begins a prospective observational study of lung cancer screening using the next-generation cancer risk test “MySignal Scan” with Hokkaido University Hospital in Hokkaido, which has the lowest c... | - |
| 21.01.2024 | Craif begins a prospective observational study of lung cancer screening using the next-generation cancer risk test “MySignal Scan” with Hokkaido University Hospital in Hokkaido, which has the lowest c... | Craif Co., Ltd.
Craif begins a prospective observational study of lung cancer screening using the next-generation cancer risk test “MySignal Scan” with Hokkaido University Hospital in Hokkaido, which has the lowest cancer screening particip... |
| 18.01.2024 | Craif appoints Yuki Yoshida as business development manager for business growth and expansion. | Craif Co., Ltd.
Craif appoints Yuki Yoshida as business development manager for business growth and expansion.
……
Craif Inc. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose,
hereinafter referred to as Craif) has appointed Yuki Yoshida, form... |
| 18.01.2024 | Craif appoints Yuki Yoshida as business development manager for business growth and expansion. | - |
| 01.12.2023 | Craif launches preferential sale of next-generation cancer risk test “MySignal Scan” through Mitsui Sumitomo Aioi Life Insurance’s healthcare service “MSA Care” | Craif Co., Ltd.
Craif launches preferential sales of next-generation cancer risk test “MySignal Scan” through Mitsui Sumitomo Aioi Life Insurance’s healthcare service “MSA Care”
……
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo; CEO: Ryuichi O... |
| 01.12.2023 | Craif launches preferential sale of next-generation cancer risk test “MySignal Scan” through Mitsui Sumitomo Aioi Life Insurance’s healthcare service “MSA Care” | 0 0 votes
Article Rating
Connect with
Login
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settin... |
| 27.10.2023 | 【「がん活」に関する調査第二弾】約8割が尿を使ったがんリスク検査に興味あり！「時間がなくても家で簡単に検査ができる」「身体への負担が少ない」など、検査の負担や予防の意識を変えると期待... | 次世代(*1)がんリスク検査「マイシグナル®︎リモートがん検査」を提供するCraif株式会社（所在地：東京都文京区、CEO：小野瀨 隆一、以下Craif）は、全国の40〜60代を対象に「がん活(*2)に関するアンケート」の第二弾を実施し、300名から回答を得ました。
*1.尿に含まれるマイクロRNAをAIで分析するがん検査技術として
*2.「がん活」とは、2人に1人が生涯のうちに罹患する「がん」と日常から積極的に向き合い、がんの早期発見やがん予防に前向きに取り組むことで、... |
| 13.10.2023 | 業界初！(*1)包括的ながん対策をサポートする、「マイシグナル®️シリーズ」11/1(水)から提供開始 | Craif株式会社（所在地：東京都文京区、CEO：小野瀨 隆一、以下Craif）は、遺伝子検査とマイクロRNA×AI検査の組み合わせで、「生まれ持った体質」と「今の体の状態」を総合的に確かめることができる、業界初(*1)の包括的ながん対策、『マイシグナル®︎シリーズ』を11月1日(水)から提供開始いたします。発売に先立ち、先行予約を本日10月13日(金)より開始いたします。(*2)
日本では高齢化が急速に進んでおり、日本人の2人に1人ががんに罹患し、3人に1人ががんで亡くな... |
| 10.10.2023 | 「がん活」は家族のがん経験者有無や男女で意識に大きな差あり！約半数ががん検診を受けたことがないが、理想は「1年に1回の受検」と回答。家族にがん経験者がいない人は、がんを自分ゴト化できていない現状... | 次世代(*1)がんリスク検査「マイシグナル®︎リモートがん検査」を提供するCraif株式会社（所在地：東京都文京区、CEO：小野瀨 隆一、以下Craif）は、全国の40〜60代を対象に「がん活(*2)に関するアンケート」を実施し、300名から回答を得ました。
*1.尿に含まれるマイクロRNAをAIで分析するがん検査技術として
*2.「がん活」とは、2人に1人が生涯のうちに罹患する「がん」と日常から積極的に向き合い、がんの早期発見やがん予防に前向きに取り組むことで、健康維持... |
| 04.11.2021 | Capital and Business Alliance with Craif, Inc. for Developing New Cancer Detection Services (47KB)PDF | November 4, 2021
Tokio Marine Holdings, Inc.
Capital and Business Alliance with Craif, Inc. for Developing New Cancer Detection Services
Tokio Marine Holdings, Inc. (President and Group CEO: Satoru Komiya, hereinafter referred to as "T... |
| - | Craif | “Craif's mission is to realize "painless, high-precision early detection of cancer" by urine testing.Craif aims to build a new society in which people do not lose their lives due to cancer.” |
| - | Craif | “Craif (Craif Co., Ltd.) is a Japanese Bio-AI startup established in 2018/5.With our unique biomarker analysis platform NANO IP and AI, we will realize the early detection of diseases such as "cancer" from MICRORNA in urine and sa... |
